Quality by Design (QbD) refers to a systematic, science-based approach to the development of medicinal products and clinical trials in which quality is built into the design of a process or product from the outset\u2014rather than being ensured only at the end through testing. The concept originates from US quality philosophy and was incorporated into the regulatory framework through the ICH guideline Q8(R2) for pharmaceutical development. <\/p>\n
At its core, Quality by Design is based on the systematic identification and control of quality-critical influencing factors. The starting point is the definition of the Quality Target Product Profile (QTPP), which describes the desired quality characteristics of the final product. From this, Critical Quality Attributes (CQAs) are derived\u2014measurable properties that directly affect the product\u2019s safety, efficacy, and quality. <\/p>\n
Subsequently, Critical Process Parameters (CPPs) are identified\u2014i.e., process parameters whose variation affects the CQAs. The Design Space defines the multidimensional space of input variables and process parameters within which the defined quality can be ensured with a high degree of probability. Changes within the Design Space do not require regulatory approval\u2014an important operational advantage over the traditional fixed-design approach. <\/p>\n
In clinical trials, the QbD concept is applied to study planning and clinical data management. Risk-based Monitoring (RBM) in accordance with ICH E6(R3) is based on the same core principle: quality risks are identified prospectively, assessed, and mitigated through targeted control measures. The Data Management Plan (DMP) defines which data points are considered critical and which review mechanisms are to be applied. <\/p>\n
In clinical data management, QbD includes defining edit checks in the electronic case report form (eCRF) already during the design phase, prospectively specifying query rules, and validating database systems in accordance with GAMP 5 and 21 CFR Part 11 and\/or EU GMP Annex 11. This upstream quality assurance reduces data errors before they enter analysis.<\/p>\n
The ICH guidelines Q8(R2), Q9(R1), and Q10 form the regulatory foundation for Quality by Design. ICH Q8(R2) describes pharmaceutical development according to QbD principles and defines concepts such as QTPP, CQA, and Design Space. ICH Q9(R1) sets out the principles of pharmaceutical quality risk management and provides tools such as FMEA (Failure Mode and Effects Analysis) and Ishikawa diagrams. ICH Q10 describes the pharmaceutical quality management system as the overarching framework. <\/p>\n
The EMA and BfArM have integrated QbD principles into their assessment practice. As part of Marketing Authorisation Applications (MAA), Module 3 of the electronic Common Technical Document (eCTD) is expected to document the development history according to QbD principles. Authorities reward a robust QbD approach with greater flexibility in post-approval change management. <\/p>\n
With the introduction of ICH E6(R3) and the increasing adoption of decentralised clinical trials, Quality by Design has also gained importance in the GCP environment. The sponsor and CRO jointly define in the study protocol and monitoring plan which data and processes are to be classified as quality-critical. On this basis, monitoring resources are allocated\u2014more intensive oversight where the risk of critical errors is highest. <\/p>\n
CAPA processes (Corrective and Preventive Actions) under GMP and GCP also reflect the QbD concept: deviations are not only corrected reactively, but systematically analysed for root causes to prevent recurrence. Full-service CROs such as mediconomics integrate QbD-compliant quality assurance into all phases of study design\u2014from feasibility to database lock. <\/p>\n
Quality by Design fundamentally changes the understanding of quality: quality is not measured at the end, but built in from the beginning. This reduces costly rework, shortens development timelines, and increases the reliability of clinical data. For sponsors seeking approval from authorities such as the EMA or BfArM, a documented QbD approach signals regulatory maturity and process control. <\/p>\n
The increasing digitalisation of clinical trials through Electronic Data Capture (EDC) systems, risk management systems, and central monitoring dashboards provides the technical infrastructure to implement QbD principles in day-to-day practice. Prospective quality criteria, defined decision thresholds, and transparent documentation are the key elements. <\/p>\n
What is the difference between Quality by Design and traditional quality control?<\/strong><\/p>\n Traditional quality control tests the finished product or completed process for compliance and detects deviations. Quality by Design, by contrast, analyses during the development phase which factors influence quality and prospectively builds control mechanisms into the process. The result is a more robust system that makes errors unlikely from the outset, rather than identifying them retrospectively. <\/p>\n How is QbD applied in a clinical trial?<\/strong><\/p>\n In clinical trials, QbD is primarily reflected in risk-based monitoring and clinical data management. The sponsor and CRO prospectively identify critical data points and processes (analogous to CQAs), define acceptable risk thresholds, and specify control measures. The monitoring plan, the Data Management Plan document, and the study plan (protocol) together form the study\u2019s quality system. <\/p>\n Which ICH guidelines are relevant for Quality by Design?<\/strong><\/p>\n The most important ICH guidelines are Q8(R2) on pharmaceutical development, Q9(R1) on quality risk management, and Q10 on the pharmaceutical quality system. For clinical trials, ICH E6(R3) (Good Clinical Practice) is key, as it sets expectations for risk-based monitoring and prospective quality assurance. In addition, ICH Q12 governs lifecycle management and, under certain conditions, allows simplified post-approval change procedures. <\/p>\n Quality by Design (QbD) refers to a systematic, science-based approach to the development of medicinal products and clinical trials in which quality is built into the design of a process or product from the outset\u2014rather than being ensured only at the end through testing. The concept originates from US quality philosophy and was incorporated into […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[],"class_list":["post-6754","glossary","type-glossary","status-publish","hentry"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6754","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6754\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=6754"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=6754"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory References<\/h2>\n
\n